Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Reviva Pharmaceuticals Holdings, Inc. - Common Stock
(NQ:
RVPH
)
0.7151
+0.0051 (+0.72%)
Streaming Delayed Price
Updated: 12:16 PM EDT, Apr 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Reviva Pharmaceuticals Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
December 20, 2024
From
Applied Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
December 17, 2024
Via
Benzinga
Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
↗
December 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 24, 2024
Via
Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
↗
October 07, 2024
The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic.
Via
Benzinga
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024
↗
August 14, 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 16, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 16, 2024
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Reviva...
Via
TheNewswire.com
Topics
Regulatory Compliance
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024
↗
May 14, 2024
RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
May 14, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 13, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 13, 2024
WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva...
Via
TheNewswire.com
Topics
Regulatory Compliance
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 09, 2024
Via
Benzinga
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
April 25, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
April 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
↗
April 15, 2024
RVPH stock results show that Reviva Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
↗
January 23, 2024
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.
Via
InvestorPlace
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
January 10, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
December 18, 2023
Via
Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
December 15, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for December 14th, 2023
December 12, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
December 11, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
↗
October 30, 2023
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) shares are surging after the company released topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 30, 2023
Via
Benzinga
Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
↗
October 30, 2023
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) announced the topline results of its pivotal Phase 3 RECOVER trial evaluating brilaroxazine, a serotonin-dopamine signaling modulator in
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
October 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 27, 2023
Via
Benzinga
Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
September 29, 2023
Via
ACCESSWIRE
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
September 22, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
